MedTrace Logo

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

NCT06478693 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-12-18

No results posted yet for this study

Summary

This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.

Conditions

Interventions

DRUG

MT-303

MT-303

DRUG

MT-303 +Atezolizumab + Bevacizumab

MT-303 in combination with Atezo/Bev

Sponsors & Collaborators

  • CREATE Medicines

    collaborator UNKNOWN

  • Myeloid Therapeutics

    lead INDUSTRY

Principal Investigators

  • Matthew Maurer, MD · Myeloid Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-01
Primary Completion
2027-12-31
Completion
2028-05-31

Countries

  • Australia
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06478693 on ClinicalTrials.gov